Vasculitides

Rosalind T., 74, a hospice chaplain still running her weekly grief-support group, has just been diagnosed with giant cell arteritis. Nobody disputes that she needs a steroid-sparing agent — the disagreement is which of two options, both carrying a boxed warning, is the safer bet for her specifically.

Warren K., 68, is in remission on weekly tocilizumab for new-onset GCA. The case everyone once pointed to for stepping him down to every-other-week dosing has since been re-tested by its own three-year extension — and the answer changed.

Ines M., 79, a seamstress six weeks into the standard glucocorticoid taper for GCA, is already showing the bone and blood-sugar cost of the steroid she's on. The disagreement is whether her own accumulating side effects justify a faster, less-proven taper over the standard one.

Douglas F., 66, backstage carpenter for the community theater, is on his fourth glucocorticoid taper attempt for polymyalgia rheumatica — and has picked up two new diagnoses along the way from the steroids themselves. The disagreement is what a modestly-sized trial's benefit actually buys a patient who has this much to lose from another round of steroids.

Priyanka D., 24, runs the overnight shift in a hospital chemistry lab and has relapsed twice with Takayasu arteritis. The best evidence anyone can offer her comes from a trial that missed its own primary endpoint — in a different disease entirely.

Marcus L., 63, has large-vessel GCA that never announced itself with a single symptom — it was found on imaging. The disagreement is whether the same scan that found his disease should also be the thing that decides how long he stays on treatment.

Eleanor P., 77, volunteers twice a week at the library where she worked for decades, and her GCA has just broken through fourteen months of tocilizumab that had otherwise controlled it completely. Neither drug on the table was ever tested in a patient whose disease escaped the one that was supposed to prevent exactly this.

Gerald N., 51, a high school shop teacher, has new nerve damage from eosinophilic granulomatosis with polyangiitis — and his ANCA status turns out to put him on the weaker side of the evidence for the drug everyone would otherwise reach for first.

Tomer A., 29, drives for a rideshare app around the rhythm of Behçet's disease he's managed for five years, and a new pulmonary artery aneurysm has just raised the stakes considerably. The disagreement is which aggressive treatment actually has the safety edge everyone assumes it does, once the real trial numbers are read closely.

Dana W., 42, a third-grade teacher, has new adult-onset IgA vasculitis with mild kidney involvement — a disease pediatrics almost never has to make this call on, since it usually resolves on its own in children. The disagreement is whether a framework borrowed from a different kidney disease is the right ruler for her risk.

Carl B., 55, has run his own auto-repair shop for twenty-two years without a sick day, and is now losing the use of both feet to polyarteritis nodosa. His risk score comes back reassuringly low — but that score was only ever built to predict death, not the exact thing actually happening to him.

Marisol V., 35, a freelance graphic designer, has spent months tracking skin nodules from cutaneous polyarteritis nodosa with nothing pointing to systemic disease. The disagreement is how much a prolonged, relapsing course should worry the room, once the real natural history says that's the norm for this disease, not a warning sign — and how carefully the chosen drug itself needs to be screened for before it starts.